Floatz logo

Therapeutic Asset Ratings

146 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Olanzapine-Samidorphan
Schizophenia Disorder
New York State Psychiatric InstituteP4BBB (72)
Axs-05
Agitation in Patients With Dementia of the Alzheimer's Type
Axsome Therapeutics, Inc.P3BB (70)
Tas-102
Stage IV Non-Small Cell Lung Cancer AJCC v7
Taiho Pharmaceutical Co., Ltd.P3BB (68)
Tas-102
Stage IV Renal Cell Cancer
ExelixisP3BB (68)
Tas-102
Carcinoma, Islet Cell
National Cancer Institute (NCI)P3BB (66)
Olanzapine-Samidorphan
Bipolar Disorder I or II
New York State Psychiatric InstituteP4BB (65)
Olanzapine-Samidorphan
Schizoaffective Disorder
New York State Psychiatric InstituteP4BB (65)
Tas-102
Colorectal Cancer
STCube, Inc.P3BB (65)
Bcd-217
Melanoma Metastatic
BiocadP3BB (64)
Begev
Classical Hodgkin Lymphoma Relapsed
Cairo UniversityP3BB (64)
Axs-05
Major Depressive Disorder
Axsome Therapeutics, Inc.P4B (63)
Axs-05
Agitation, Psychomotor
Axsome Therapeutics, Inc.P3B (63)
nd0612
Parkinson's Disease
NeuroDerm Ltd.P3B (63)
Axs-05
Agitation
Axsome Therapeutics, Inc.P3B (62)
Tas-102
Duct Cell Adenocarcinoma of the Pancreas
Taiho Pharmaceutical Co., Ltd.P2B (62)
Tas-102
Refractory Multiple Myeloma
National Cancer Institute (NCI)P2B (62)
Karxt
Agitation
Bristol-Myers SquibbP3B (60)
Karxt
Autism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyP3B (60)
Karxt
Bipolar Disorder Type I With Mania
Bristol-Myers SquibbP3B (60)
Tas-102
Carcinoma
Symphogen A/SP3B (60)
Karxt
Schizophrenia
Karuna Therapeutics, Inc., a Bristol Myers Squibb companyP3B (59)
Tas-102
Colorectal Neoplasms
Bristol-Myers SquibbP3B (59)
Tas-102
Metastatic Colorectal Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd.P3B (59)
Tas-102
Rectal Cancer
Shandong Cancer Hospital and InstituteP3B (59)
Tas-102
Rectal Cancer Patients
Shandong Cancer Hospital and InstituteP3B (59)
Showing 1 to 25 of 146 assets
PreviousPage 1 of 6Next